Examkin

Soru

Zorluk: Çok zorMedical History Evaluation

A 74-year-old man is brought to the emergency department by his daughter due to a 1-day history of passing dark, tarry stools, accompanied by severe lightheadedness and profound fatigue. His medical history is significant for nonvalvular atrial fibrillation, essential hypertension, and benign prostatic hyperplasia. His home medications include apixaban 5 mg twice daily, lisinopril, and tamsulosin.

Three days ago, the patient was evaluated at an urgent care clinic for a severe cough and fever; he was diagnosed with a presumed atypical respiratory infection and prescribed a 5-day course of clarithromycin. The daughter also notes that the patient began taking a daily over-the-counter Ginkgo biloba extract two weeks ago to "help with his memory."

On physical examination, the patient appears pale and diaphoretic. His temperature is 37.1°C (98.8°F), blood pressure is 88/54 mm Hg, and heart rate is 118/min. Digital rectal examination reveals gross melena.

Laboratory studies obtained on admission:
Hemoglobin: 7.2 g/dL (baseline 13.8 g/dL one month ago)
Platelet count: 185,000/mm³
Serum creatinine: 1.2 mg/dL (baseline 1.1 mg/dL)
Weight: 82 kg (180 lbs)

Based on the evaluation of this patient's medical and pharmacological history, which of the following elements represent the primary precipitating factors for his acute hemorrhagic presentation? (Select all that apply)

  1. The addition of clarithromycin to his medication regimenCevap
  2. The recent initiation of Ginkgo biloba supplementationCevap
  3. C
    The administration of a 5 mg twice-daily dose of apixaban given his age and weight
  4. D
    The co-administration of tamsulosin with a direct oral anticoagulant
  5. E
    The physiological stress and systemic inflammation induced by the acute respiratory infection

Cevap

The primary precipitating factors for this patient's acute hemorrhage are the addition of clarithromycin to his medication regimen and the recent initiation of Ginkgo biloba supplementation.
The correct elements that precipitated the hemorrhage are the addition of clarithromycin and the initiation of Ginkgo biloba. Clarithromycin is a strong inhibitor of both Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Because apixaban is metabolized by CYP3A4 and is a substrate of P-gp, co-administration with clarithromycin drastically reduces apixaban clearance, causing supratherapeutic anticoagulant levels. Concurrently, Ginkgo biloba is an herbal supplement known to inhibit platelet-activating factor (PAF). When combined with systemic anticoagulation, it synergistically increases the risk of major hemorrhage.

Adım Adım Çözüm

1
Identify the primary clinical presentation.
The patient is presenting with acute, massive upper gastrointestinal hemorrhage (melena, symptomatic anemia, hypotension).
Establishing the acute problem directs the focus of the medical history review toward bleeding etiologies.
2
Evaluate the medication history for pharmacokinetic interactions.
The patient was recently prescribed clarithromycin while taking apixaban.
Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein, the primary metabolic and efflux pathways for apixaban, leading to toxic drug accumulation.
3
Analyze the supplementary and herbal history.
The patient recently started taking Ginkgo biloba.
Ginkgo biloba inhibits platelet-activating factor (PAF), conferring an independent bleeding risk that acts synergistically with systemic anticoagulation.
4
Rule out baseline iatrogenic dosing errors.
The patient is 74 years old, weighs 82 kg, and has a creatinine of 1.2 mg/dL. He does not meet criteria for apixaban dose reduction.
Apixaban dose reduction (to 2.5 mg twice daily) requires at least two of three criteria: age \geq 80 years, weight \leq 60 kg, or serum creatinine \geq 1.5 mg/dL. Because he meets none, his baseline dose of 5 mg twice daily was correct.

Anahtar Kavram

The evaluation of acute hemorrhage in a patient taking a direct oral anticoagulant requires careful reconciliation of recent medication additions (e.g., strong CYP3A4/P-gp inhibitors like clarithromycin) and herbal supplements (e.g., Ginkgo biloba) that synergistically amplify bleeding risk.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Medical History Evaluation

Bu konudan daha fazla soru